6/13/2019
`
`Integrated solution provider for phamiaceutical industry “From upstream to downstream" | Sumitomo Corporation in North, Central and S...
`
`Sumitomo Corporation | Enriching lives and the world
`
`ggdinlfnqufizlaand
`
`'1-
`ba
`
`5
`
`‘1‘-
`
`~
`
`ases
`
`Global Based One-stop Shop for Pharmaceutical
`Industry
`
`
`
`The pharmaceutical industry has evolved remarkably since the latter half of the 20th century, so much so that
`
`some people are calling the 21st century "the century of pharmaceuticals.” The development of new drugs and the
`
`sourcing of materials for drugs are now conducted beyond countries and pharmaceutical companies are operated
`
`in a global basis.
`
`Engaging together with its subsidiaries in its pharmaceuticals business, Summit Pharmaceuticals International
`
`Corporation (SPI), Summit Pharmaceuticals Europe(SPE) and Summit Pharmaceuticals China(SPC), Sumitomo
`
`Corporation offers comprehensive support to players in both the upstream and downstream segnmggafmibit 2015
`Sawai v. B'
`en
`Page 1 of 7
`https://www.sumitomocorp.com/en/us/business/case/groupl236
`159g
`IPR2019-00789
`
`

`

`6/13/2019
`
`Integrated solution provider for phamiaceutical industry “From upstream to downstream" | Sumitomo Corporation in North, Central and S...
`
`pharmaceutical industry. We not only support the R&D of but also supply materials for new drugs and generic
`
`drugs by taking advantage of its long and broad experience and unique global structure as a general trading
`
`company. Through these activities, Sumitomo Corporation broadly contributes to the improvement of people’s
`
`quality of life worldwide.
`
`For the discovery and clinical trial stages, we do investments and lending in pharmaceutical ventures and provide
`
`agency services for research alliances and licenses. For later developmental and commercial stages, we select
`
`appropriate suppliers from manufacturers inJapan, Europe, India, China, Korea, etc. and provide materials and
`
`formulations to pharmaceutical companies that produce new drugs as well as generic drugs. We also help foreign
`
`manufacturers to apply for the registrations like Foreign Manufacturer Accreditation(FMA) and Master File(MF) in
`
`Japan. In addition, API Laboratory (Kawasaki City) has been established to ensure the supply of high-quality APIs
`
`conforming to specifications, by carrying out quality analysis by its own staffs.
`
`
`
`Inside the API Laboratory in Kawasaki.
`
`Contribution to Drug Discovery
`
`
`
`In the area of drug discovery instruments, SPI provides
`
`With the phenomenal development of life sciences
`
`research, the roles played by drug discovery
`
`instruments, bio-resource materials, and drug
`
`discovery technology have become increasingly
`
`important. SPI distributes several products and
`
`provides related services in drug discover area.
`
`in vivo imaging instrument for non-invasive
`
`Page 2 of 7
`https://www.sumitomooorp.oom/en/us/business/case/groupl236
`
`2/7
`
`

`

`*+,-.+/-,0ÿ2.34.ÿ-5ÿ,+.ÿ64*40-,0ÿ.+ÿ.37ÿ8-9-,0ÿ:+6;<ÿ+=
`
`

`ÿ ÿ


`

ÿ

ÿ

 
`  ÿ

ÿ

ÿ

` ÿ ÿ

` ÿ ÿ! ÿ"



ÿÿ#

$ÿ"
`

ÿ ÿ!%
`  
`E,ÿK-9+ÿE*40-,0ÿL+/A*ÿPUOV
`.37ÿ>/+0/755ÿ4,6ÿ3748-,0ÿ>/+?755ÿ+=ÿ6-574575@
`?+,./-:A.-,0ÿ.+ÿ.37ÿ67978+>*7,.ÿ+=ÿ:45-?ÿ4,6ÿ6/A0
`6-5?+97/;ÿ/7574/?3ÿ-,ÿ8-=7ÿ5?-7,?7BÿCDEF5ÿCA>>+/.ÿG7,.7/
`-,ÿH+I+34*4ÿ+==7/5ÿ?+*>/737,5-97ÿ?A5.+*7/ÿ5A>>+/.@
`-,?8A6-,0ÿ-,5./A*7,.ÿ67*+,5./4.-+,@ÿJA48-.;
`-,5>7?.-+,@ÿ/7>4-/@ÿ*4-,.7,4,?7@ÿ4,6ÿ?+,5A8.4.-+,ÿ+,
`-,5./A*7,.ÿ4>>8-?4.-+,5BÿCDEÿ485+ÿ3+865ÿ.37ÿE,ÿK-9+
`E*40-,0ÿL+/A*ÿ@ÿ-,ÿM3-?3ÿ8746-,0ÿ5?-7,.-5.5ÿ0-97
`>/757,.4.-+,5ÿ+,ÿ.37ÿ84.75.ÿA575ÿ+=ÿ.37ÿ-,5./A*7,.5ÿ=+/
`?A5.+*7/5BÿN49-,0ÿ:77,ÿ3786ÿOPÿ.-*75@ÿ.37ÿ=+/A*ÿ-5
`4../4?.-,0ÿ-,?/745-,0ÿ4..7,.-+,B
`E,ÿ.37ÿ4/74ÿ+=ÿ6/A0ÿ6-5?+97/;ÿ5A>>+/.@ÿCDEÿ+==7/5
`57/9-?75ÿ.34.ÿ*77.ÿ=/+,.8-,7ÿ,7765@ÿM3-?3ÿ-,?8A67
`-,.7/*76-4.-,0ÿ=+/ÿ,7Mÿ6/A0ÿ8-?7,575ÿ4,6ÿ/7574/?3
`488-4,?75ÿ45ÿM788ÿ45ÿ>/+9-6-,0ÿ:-+Q/75+A/?7ÿ*4.7/-485@
`5A?3ÿ45ÿ?788ÿ8-,75ÿ4,6ÿ07,7.-?ÿ*4.7/-48ÿ=+/ÿ/7574/?3ÿ-,
`R4>4,BÿS74,M3-87@ÿ+97/ÿ.37ÿTUQ>8A5ÿ;74/5ÿ5-,?7ÿ-.
`7,.7/76ÿ.37ÿ6-5./-:A.-+,ÿ:A5-,755ÿ+=ÿ:-+Q/75+A/?7
`*4.7/-485@ÿCDEÿ345ÿ7,34,?76ÿ.37ÿ8-,7A>5ÿ+=ÿ07,7
`97?.+/5@ÿ?788ÿ8-,75ÿM-.3ÿ07,7.-?ÿ*A.4.-+,5@ÿ-DCÿ?788Q
`/784.76ÿ*4.7/-485ÿ4,6ÿ5+ÿ+,BÿE,ÿ/7?7,.ÿ;74/5@ÿCDEÿ345
`485+ÿ:70A,ÿ6-5./-:A.-+,ÿ+=ÿ3-03QJA48-.;ÿ3A*4,ÿ.-55A7
`54*>875ÿ5.+/76ÿ4=.7/ÿ/7*+976ÿ:;ÿ5A/07/;ÿ.+ÿ/7574/?3
`.+07.37/ÿM-.3ÿ-,=+/*4.-+,ÿ+,ÿ.37ÿ>/7Qÿ4,6ÿ>+5.Q
`+>7/4.-+,ÿ3-5.+/;ÿ+=ÿ6-57457ÿ4,6ÿ./74.*7,.B
`CDEÿ345ÿ485+ÿ84A,?376ÿ,7Mÿ-,-.-4.-975ÿ-,ÿ.37ÿ4/74ÿ+=ÿ4/.-=-?-48ÿ-,.788-07,?7ÿ2WE<ÿ6/A0ÿ6-5?+97/;@ÿM3-?3ÿ-5ÿ4,.-?->4.76ÿ.+
`7,34,?7ÿ>/+6A?.-9-.;ÿ-,ÿ.37ÿ>/+?755ÿ+=ÿ6/A0ÿ6-5?+97/;BÿC>7?-=-?488;@ÿ.37ÿ?+*>4,;ÿ345ÿ:77,ÿA.-8-X-,0ÿWEÿ.7?3,+8+0;
`4,6ÿ64.4ÿ?+*>-876ÿ:;ÿ>34/*4?7A.-?48ÿ?+*>4,-75ÿ.+ÿ67978+>ÿ.7?3,+8+0-75ÿ=+/ÿ5A:5.4,.-488;ÿ/76A?-,0ÿ.37ÿ?+5.5ÿ4,6
`.-*7ÿ/7JA-/76ÿ-,ÿ.37ÿ?+*>+A,6ÿ+>.-*-X4.-+,ÿ5.407BÿE,ÿ+/67/ÿ.+ÿ7Y.7,6ÿ?+*>/737,5-97ÿ5A>>+/.ÿ=+/ÿ/7574/?3ÿ4,6
`67978+>*7,.ÿ-,ÿ.37ÿ>34/*4?7A.-?48ÿ-,6A5./;@ÿCDEÿ>/+9-675ÿ*A8.-=4?7.76ÿ57/9-?75ÿ:;ÿ?+884:+/4.-,0ÿM-.3
`:-+.7?3,+8+0;ÿ?+*>4,-75ÿ4,6ÿ/7574/?3ÿ-,5.-.A.-+,5ÿ-,ÿ4,6ÿ+A.5-67ÿR4>4,Bÿ?+*:-,-,0ÿM-.3ÿ3A*4,ÿ.-55A7ÿ54*>875@
`:-+*4/I7/ÿ/7574/?3ÿ4,6ÿWEÿ.7?3,+8+0;BÿW5ÿ4ÿ*7*:7/ÿ+=ÿ.37ÿCA*-.+*+ÿG+/>+/4.-+,ÿZ/+A>@ÿCDEÿ4-*5ÿ.+ÿ5A>>+/.ÿ.37
`:-+.7?3ÿ4,6ÿ>34/*4?7A.-?48ÿ-,6A5./-75@ÿM-.3ÿ-.5ÿ57/-75ÿ+=ÿ-,.70/4.76ÿ[\]ÿ5A>>+/.ÿ57/9-?75B
` & ' 

'
`  (
`  
` 

 
` )
`
`Page 3 of 7
`
`

`

`6/13/2019
`
`Integrated solution provider for pharmaceutical industry “From upstream to downstream" | Sumitomo Corporation in North, Central and S...
`
`Supporting the Penetration of Generic Drugs in
`
`
`
`Japan
`
`The term "generic drug" is now in common. In fact, many people may have had the experience of being asked by
`
`their prescribing physician whether or not they would prefer a generic drug. So what are generic drugs? When
`
`patents for new drugs expire, drugs made of the same components and with the same efficacy are put on the
`
`market. These are called generic drugs. Their advantage is that they can be offered at lower prices because they do
`
`not entail development costs.
`
`SPI supplies APIs to generic drug manufacturers. Taking advantages of the global network of the Sumitomo
`
`Corporation Group, SP1 selects, from all over the world, suppliers of high-quality APIs that demonstrate strong
`
`price competitiveness. It then conducts specification setting and quality testing of these ingredients at its API
`
`Laboratory, which is equipped with cutting-edge analyzers. By ensuring a stable supply of competitive, quality-
`
`controlled APIs, SPI helps reduce the cost of generic drugs as well as achieve their stable supply.
`
`The market share of generic drugs in volume accounted for around 65.8% ofJapan’s pharmaceutical industry as of
`
`September, 2017. TheJapanese government promotes the use of generic drugs with the ambitious goal of
`
`boosting their share to 80% until September 2020.
`
`By supporting the popularization of generic drugs, the Sumitomo Corporation Group not only contributes to
`
`reducing the economic burden on individual patients but also helps control medical healthcare expenses in Japan
`
`as a whole.
`
`Providing Marketing Innovating Drugs in the
`United States and Emerging Countries
`
`
`
`Today, the US market accounts for some 40% of the
`
`entire global pharmaceuticals market of approximately
`
`127 trillion yen. While demand for pharmaceuticals in
`
`the United States is expected to continue to rise as its
`
`population ages, its government is seeking to reduce
`
`medical expenditures. This situation provides generic
`
`Page 4 of 7
`https://www.sumitomocorp.com/en/us/business/caselgroup/236
`
`4/7
`
`

`

`6/13/2019
`
`Integrated solution provider for pharmaceutical industry “From upstream to downstream" | Sumitomo Corporation in North. Central and S...
`
`
`
`USL head office (Minnesota, USA)
`
`drugs an opportunity to play a wider role. Through
`
`Sumitomo Corporation of Americas, Sumitomo
`
`Corporation acquired a 20% stake in Upsher-Smith
`
`Laboratories, (USL), a generic pharmaceutical
`
`company owned by a US subsidiary of Sawai
`
`Pharmaceutical and entered into the US generic
`
`pharmaceuticals market. USL has been engaged in
`
`research and development, manufacture and sale of
`
`generic drugs, having its strong development, stable
`
`supply and robust sales capabilities as well as a solid
`
`customer base built up over many years of business.
`
`Sumitomo Corporation will capitalize on its strengths
`
`as an integrated trading company to support USL's
`
`business management by supplying materials for
`
`drugs and helping USL put new products on the
`
`market. By widely offering high quality generic drugs
`
`through USL, we hope to contribute people’s health
`
`and enjoying their life.
`
`Meanwhile, pharmaceutical markets in such countries
`
`as Brazil, Russia and Turkey are expanding rapidly as
`
`their economies develop and living standards rise. The
`
`growth rates of drug markets in these countries,
`
`known as ”emerging pharmaceuticals markets,"
`
`exceed the average growth rate of the global drug
`
`market. By 2021, these emerging pharmaceuticals
`
`markets are projected to account for around one
`
`fourth of the entire global market. Sumitomo
`
`Corporation intends to strengthen its relationship with
`
`local pharmaceutical companies in these countries to
`
`support their introduction of biopharmaceuticals and
`
`government-backed local production, thereby
`
`stepping up its efforts to promote people's health and
`
`enrich their lives.
`
`Page 5 of 7
`httpszllwwwsumitomooorp.oom/en/us/business/case/group/236
`
`5/7
`
`

`

`6/13/2019
`
`Integrated solution provider for pharmaceutical industry “From upstream to downstream" | Sumitomo Corporation in North, Central and S...
`
`Related Information
`
`0 Serving the UK Medical Research Nonprofit LifeArc as a General Agent
`
`0 Summit PharmaceuticalsInternational
`
`LU
`
`June 2018
`
`Keyword
`
`Mineral Resources, Energy, Chemical & Electronics Business /Japan /East Asia /The Americas /Chemica| Electronics
`
`Related Cases
`
`
`
`0 Addressing to
`
`0 Making People
`
`0 Ensuring Japan's
`
`0 Stable supply of
`
`food safety and
`
`Around the
`
`Future through
`
`a key material of
`
`security through
`
`World More
`
`Support for the
`
`power sources
`
`veterinary
`
`medicine for
`
`livestock
`
`Beautiful
`
`Through
`
`Cosmetics
`
`Page 6 of7
`https://www.sumitomocorp.com/en/us/business/caselgroup/236
`
`Pharmaceutical
`
`for advanced
`
`Industry E'
`
`equipment
`
`6/7
`
`

`

`6/13/2019
`
`Integrated solution provider for pharmaceutical industry “From upstream to downstream" | Sumitomo Corporation in North, Central and S...
`
`Home
`
`> Our Business
`
`> Global Cases
`
`>
`
`Integrated solution provider for pharmaceutical industry ”From upstream to
`
`downstream"
`
`© 2018 Sumitomo Corporation
`
`Page 7 of 7
`httpszllwww.sumitomooorp.oonVen/us/business/case/group/236
`
`7/7
`
`